REGN

Regeneron screens as a high-quality business trading at a discounted multiple. At $609.94 the stock fetches just 14.7x FY2025 diluted EPS of $41.48 and 3.9x sales, undemanding for a company posting a 31.4% net margin, a 24.9% operating margin and converting earnings to roughly $4.08B of free cash flow (OCF $4.98B less capex $898M). The balance sheet is a fortress: $31.3B of equity against only $9.30B of liabilities (0.30x), $3.12B cash versus $1.99B long-term debt — effectively net cash — leaving ample room to fund the $3.44B buyback (up 32%), a $370M dividend and opportunistic M&A without strain. ROE of 14.4% is respectable given how much equity sits idle as cash.

The catch, and the reason this is a moderate-conviction buy rather than a slam dunk, is growth. Revenue rose just 1.0% to $14.3B and operating income actually fell 10.3% to $3.58B as R&D climbed 14% to $5.85B — net income (+2.1%) and EPS (+8.2%) were flattered by buybacks and below-the-line items more than by core operating leverage. The five-year history shows the post-COVID reset plainly: revenue peaked at $16.1B and net income at $8.08B in FY2021, then earnings roughly halved and have only crept back toward $4.5B. The 10-K is candid that the company is 'substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent,' and flags biosimilar/Aflibercept competition plus drug-price-control measures as direct threats to the most concentrated part of the franchise.